ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0568

Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)

Amy Joseph1, Jodi Yanagida1, Xinliang Huang1, Prabha Ranganathan1, Melissa Laurie2, Hong Xian1 and Seth Eisen1, 1VA St. Louis Health Care System, St. Louis, MO, 2Bristol Myers Squibb, Princeton, NJ

Meeting: ACR Convergence 2021

Keywords: Anti-CCP, Diagnostic criteria, registry, rheumatoid arthritis, Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Epidemiology & Public Health Poster II: Inflammatory Arthritis – RA, SpA, & Gout (0560–0593)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The Department of Veterans Affairs (DVA) provides comprehensive medical care at minimal or no cost to 9 million veterans annually through 170 medical centers and 1074 outpatient clinics across the United States. In 1999, the DVA established a national, fully integrated electronic health record (EHR), which now includes approximately 24 million veterans. However, few studies have used Veterans Affairs (VA) EHR data to examine the validity of diagnoses of RA. We developed a validated, national database of patients with RA who received VA care since the introduction of International Classification of Diseases, tenth revision (ICD-10) coding in 2015. This Veterans Affairs National Rheumatoid Arthritis Database (VANRAD) will provide infrastructure for retrospective and prospective research to address the ‘real-world’ care of patients with RA.

Methods: Patients with the following criteria were identified from the VA EHR as of October 2, 2020: (a) ≥1 ICD-10 diagnosis code of RA; (b) treatment with ≥1 DMARD; (c) ≥2 VA rheumatology clinic visits; and (d) ≥1 RF and/or anti-CCP (aCCP) antibody test result. From this group, 553 EHRs were randomly selected for review. The ‘gold standard’ for the diagnosis of RA was the treating rheumatologist’s diagnosis, documented in the EHR.

Results: A total of 27,482 patients met eligibility criteria. Sociodemographic characteristics were: 85.6% male; mean age of 69.7 years (y) (standard deviation [SD]=10.9 y; range=21.9 y to 100.5 y); 76.4% white, 17.0% African American; and mean VA care for 14.1 y (SD=5.3 y, range=0.04 y to 20.0 y).

For patients with ≥1 RF or aCCP test, the positive predictive value (PPV) for RA ranged from 65.3% (RF-/aCCP-) to 95.8% (RF+/aCCP+); rheumatologists’ likelihood of a ‘possible’ diagnosis was higher if the aCCP test result was negative or not available (Table 1). Excluding patients with a second rheumatologic diagnosis did not improve PPV results (data not shown).

The percentage of RA-confirmed patients with 1 test not available, and whose complementary test was negative (RF0/aCCP- or RF-/aCCP0), was greater than the percentage of patients for whom both tests were negative (RF-/aCCP-). This suggests our data extraction methods may have been incomplete or that unidentified bias may have been present, and warrants further study.

Conclusion: Our methodology for constructing an RA database by selecting patients with ≥2 rheumatology clinic visits, an ICD-10 diagnosis of RA, treatment with ≥1 DMARD, and a minimum of 1 RF or aCCP test result has high positive predictive value for RA. Positive RF and aCCP test results were strong predictors of rheumatologists’ diagnostic certainty for an RA diagnosis. Thus, the VANRAD and the associated EHR provide opportunity for a wide range of retrospective observational and prospective longitudinal studies based on ‘real-world’ patient care.

References: Ng B, et al. Arthritis Care Res 2012;64:1490-6; Hanly JG, et al. Open Access Rheumatol 2015;7:69-75.

Original abstract © 2020 EULAR/BMJ


Disclosures: A. Joseph, Bristol Myers Squibb, 5; J. Yanagida, None; X. Huang, Washington University in St. Louis, 3; P. Ranganathan, None; M. Laurie, Bristol Myers Squibb, 3, 11; H. Xian, Bristol Myers Squibb, 5; S. Eisen, Bristol Myers Squibb, 7.

To cite this abstract in AMA style:

Joseph A, Yanagida J, Huang X, Ranganathan P, Laurie M, Xian H, Eisen S. Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/construction-of-the-veterans-affairs-national-rheumatoid-arthritis-database-vanrad/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/construction-of-the-veterans-affairs-national-rheumatoid-arthritis-database-vanrad/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology